MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
6.38
+0.14
+2.24%
After Hours: 6.36 -0.02 -0.32% 19:30 02/06 EST
OPEN
6.44
PREV CLOSE
6.24
HIGH
6.44
LOW
6.26
VOLUME
6.35M
TURNOVER
--
52 WEEK HIGH
11.31
52 WEEK LOW
6.00
MARKET CAP
1.58B
P/E (TTM)
-134.8837
1D
5D
1M
3M
1Y
5Y
1D
Is Biocryst Pharmaceuticals (BCRX) Attractively Priced After Extended Share Price Weakness?
Simply Wall St · 19h ago
BioCryst Uses Equity Grants To Support Rare Disease Pipeline And Talent
Simply Wall St · 2d ago
BioCryst reports inducement grants under Nasdaq listing rule
TipRanks · 3d ago
BioCryst Pharmaceuticals kündigt Veröffentlichung neuer Finanzergebnisse an
Reuters · 3d ago
BioCryst Pharmaceuticals Inc. to Report Fourth Quarter Financial Results
Reuters · 3d ago
BioCryst Pharmaceuticals gewährt neuen Mitarbeitern Aktienoptionen und RSUs als Teil des Vergütungsplans
Reuters · 3d ago
BioCryst Grants Stock Options and RSUs to New Employees Under Inducement Plan
Reuters · 3d ago
BIOCRYST REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 3d ago
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.